InvestorsHub Logo
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

Re: TheFinalCD post# 160

Tuesday, 09/27/2022 7:29:53 AM

Tuesday, September 27, 2022 7:29:53 AM

Post# of 197
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AQST News